MONMOUTH JUNCTION, NJ--(Marketwire - May 14, 2008) - TyRx Pharma, Inc., the leader in the marketing of convergent drug -- device products, announced today that the first commercial implant of the AIGISRX™ Anti-Bacterial Envelope in a CRMD procedure was conducted at St. Luke’s Episcopal Hospital of the Texas Heart Institute in Houston. The new antibacterial envelope device is designed to stabilize pacemakers (IPG) and implantable cardioverter defibrillators (ICD) with the additional benefit of reducing potential risks of infections associated with implantation.
